Get the Stockscreener App
1.58
6.51%
-0.11
Pre-market:
1.60
0.02
+1.27%
Enlivex Ltd stock is traded at $1.58, with a volume of 341.42K.
It is down -6.51% in the last 24 hours and down -73.88% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$1.69
Open:
$1.71
24h Volume:
341.42K
Relative Volume:
2.11
Market Cap:
$26.59M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.062
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
-24.04%
1M Performance:
-73.88%
6M Performance:
-90.51%
1Y Performance:
-94.08%
1-Day Range:
$1.53
$1.71
1-Week Range:
$1.53
$2.18
52-Week Range:
$1.53
$31.50
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
1.58 | 30.97M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Enlivex Ltd. SEC Filing (Aug 14, 2026) - Stock Titan
Enlivex Ltd. (ENLV) sees 9.99% stake reported via convertible note - Stock Titan
Enlivex Restructures $19.2 Million Convertible Note With Lind, Easing Default Risk - TipRanks
Enlivex (ENLV) revises $21M secured convertible note, adds 10% interest trigger - Stock Titan
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
ENLV Stockholders Plan Sale of 10 Million Shares Amidst Challenging Valuation Landscape - GuruFocus
Enlivex Ltd. (NASDAQ: ENLV) files to register 10M shares for noteholder resale - Stock Titan
Enlivex (ENLV) Climbs 3.83% to $2.17 as Shares Press Against $2.28 ResistanceVolume Spike Alerts - dars.gov.et
ENLV Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
H.C. Wainwright Lifts Enlivex Therapeutics (ENLV) Price Target t - GuruFocus
H.C. Wainwright raises Enlivex stock price target to $80 on token gains - Investing.com
Weekly Recap: HC Wainwright & Co. PT hike and Rain Foundation financing - TradingView
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June - marketscreener.com
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones - marketscreener.com
Enlivex Ltd. announced that it expects to receive $400 million in funding - marketscreener.com
Enlivex prices USD 400 million private placement at USD 5 per share - Bitget
Enlivex: Price Is $5/Shr for Subscription Amounts Funded in U.S. Dollars, USDT or USD Coin >ENLV - Moomoo
ENLV Stock Slides Into 1-For-15 Reverse Split On Nasdaq - StocksToTrade
Enlivex (ENLV) Secures $400M Private Placement at Premium Pricing - GuruFocus
Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens - TipRanks
Enlivex Announces $400,000,000 Private Placement - marketscreener.com
Enlivex (Nasdaq: ENLV) sets $400M RAIN token-linked private placement - Stock Titan
Enlivex investor may fund proposed $400M deal with RAIN tokens - Stock Titan
ENLV|Enlivex Therapeutics Ltd|Price:4.250|Chg%:+0.050 - TradingKey
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Market Sentiment - Benzinga España
Enlivex Therapeutics Ltd (ENLV) Balance Sheet - TradingKey
Enlivex Therapeutics Ltd (ENLV) Cash Flow - TradingKey
Enlivex Therapeutics Ltd (ENLV) Income Statement - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Institutional Confidence - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex(ENLV) Stock Options Chain | Quotes & News - Moomoo
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enlivex Ltd (1BT.DU) latest press releases and corporate news - Yahoo Finance UK
Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2% - MarketBeat
Enlivex Therapeutics (NASDAQ:ENLV) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Enlivex Ltd (1BT.DU) stock price, news, quote and history - Yahoo Finance UK
Enlivex Ltd. (ENLV) Q4 2025 Earnings: Massive EPS Discrepancy Reflects Non-Recurring Charges; Pipeline Progress ContinuesPreliminary Results - dars.gov.et
Enlivex Ltd. (ENLV) Posts Modest Gains as Shares Consolidate Near SupportRisk Reward Setups - dars.gov.et
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share - The Globe and Mail
Enlivex Ltd. (ENLV) Rallies 1.71% – Testing Key Resistance at $5.0RVOL Spike - dars.gov.et
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion - The Manila Times
Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV - Stock Titan
Enlivex’s Net Asset Value Per Share Was $66.16 on July 18 - Stock Titan
Enlivex Ltd. (ENLV) upgraded to buy: Here's why - MSN
Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment - GuruFocus
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis - TipRanks
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why - Yahoo Finance
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):